Compare AbCellera Biologics Inc (ABCL) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Jones Lang LaSalle Inc — how do they compare? AbCellera Biologics Inc trades at $9.1 (market cap $2.99B), while Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is far larger — about 5.6× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | JLL | |
|---|---|---|
Market Cap | $2.99B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $9.76 | $373.24 |
52-Week Low | $2.78 | $280.16 |
Enterprise Value | $2.58B | $19.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
